Multiple Myeloma: all 3,712 studies
Page 7 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney InjuryNot yet recruitingNCT05429515Phase 4
- Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT05422027Phase 1/2
- Multiparametric Cardiac MRI in Patients Under CAR T-cell TherapyRecruitingNCT05414162
- Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell TransplantRecruitingNCT05405387Phase 2
- Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple MyelomaRecruitingNCT05378971Not applicable
- A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT05372354Phase 1/2
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseRecruitingNCT05366881
- Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT05363111Phase 1
- Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor ConditionsRecruitingNCT05361694
- Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple MyelomaNot yet recruitingNCT05353907
- Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple MyelomaAvailableNCT05346835
- Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple MyelomaRecruitingNCT05344833Phase 2
- Long-Term Follow-up StudyEnrolling by invitationNCT05332054
- Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple MyelomaRecruitingNCT05312255Not applicable
- Efficacy and Safety Evaluation of PD1-BCMA-CARTNot yet recruitingNCT05308875Not applicable
- A Study of CM336 in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT05299424Phase 1/2
- A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome InhibitorNot yet recruitingNCT05298683Phase 2
- Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and LymphomaRecruitingNCT05294055Phase 2
- A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFHRecruitingNCT05283993
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleRecruitingNCT05280275Phase 1/2
- Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM PatientsRecruitingNCT05272826Phase 2
- A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple MyelomaRecruitingNCT05271682Phase 1
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Phase 3
- Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple MyelomaRecruitingNCT05243212Phase 1/2
- A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05219721Phase 1
- Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaRecruitingNCT05208307Phase 2
- Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.RecruitingNCT05203003
- A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Phase 4
- Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRDRecruitingNCT05192122Phase 1
- Early Integration of Palliative and Supportive Care in Cellular TherapyRecruitingNCT05190653Not applicable
- A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)Not yet recruitingNCT05181501Phase 1
- A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT05160584
- Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT05145400Phase 2
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingNCT05137054Phase 1
- Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular TherapyRecruitingNCT05135351Not applicable
- In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PETRecruitingNCT05093335Early Phase 1
- Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingNCT05092451Phase 1/2
- Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT05091372Phase 2
- A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic MalignanciesNot yet recruitingNCT05055791Phase 1/2
- Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with IsatuximabRecruitingNCT05053607Not applicable
- Two Step Haplo With Radiation ConditioningRecruitingNCT05031897Phase 2
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Phase 3
- Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic MalignanciesRecruitingNCT05011045
- Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple MyelomaRecruitingNCT05007418Phase 1
- Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell TransplantationRecruitingNCT05005299Phase 1
- A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)RecruitingNCT05001087
- Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)RecruitingNCT04991103Phase 2
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)RecruitingNCT04988555Phase 1/2
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Phase 1/2
- APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT04942067Phase 1/2
- Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMMRecruitingNCT04941937Phase 2
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04910568Phase 1
- Improving Cognitive Function in Older Adults Undergoing Stem Cell TransplantRecruitingNCT04898790Not applicable
- Methods of T Cell Depletion Trial (MoTD)RecruitingNCT04888741Phase 2
- Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"RecruitingNCT04888039
- Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT04879043Phase 1/2
- ATG-010(Selinexor) in Combination With Chemotherapy in RRMMRecruitingNCT04877275Phase 2
- Double Filtration Plasmapheresis Combined With ChemotherapyRecruitingNCT04836871Phase 1
- A Diagnostic Study of CD38-Targeted ImmunoPET of MyelomaRecruitingNCT04814615Phase 2
- A New Study Evaluating the Activity of Modular CAR T for mYelomaRecruitingNCT04795882Phase 1
- A Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseRecruitingNCT04776330Phase 1/2
- Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.RecruitingNCT04771572Phase 1
- Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial ReleaseAvailableNCT04771078
- CXCR4 Modified Anti-BCMA CAR T Cells for Multiple MyelomaRecruitingNCT04727008Phase 1
- Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT04714827Phase 1/2
- Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory HemopathiesNot yet recruitingNCT04702932
- A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple MyelomaNot yet recruitingNCT04670055Early Phase 1
- Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy AdherenceRecruitingNCT04663100Not applicable
- CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic DiseasesRecruitingNCT04662294Early Phase 1
- T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple MyelomaRecruitingNCT04662099Phase 1
- A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingNCT04661137Phase 2
- APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple MyelomaRecruitingNCT04657861Early Phase 1
- National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04634552Phase 2
- CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological MalignanciesRecruitingNCT04603872Early Phase 1
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialRecruitingNCT04566328Phase 3
- Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple MyelomaRecruitingNCT04558931Phase 2
- A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells TherapyNot yet recruitingNCT04541368Early Phase 1
- Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.RecruitingNCT04533217Not applicable
- Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.RecruitingNCT04519476Phase 1
- The Relapse from MRD Negativity As Indication for Treatment (REMNANT) StudyRecruitingNCT04513639Phase 2/3
- Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaRecruitingNCT04508790Phase 2
- Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative DiseasesRecruitingNCT04504526Early Phase 1
- Personalized Autologous Transplant for Multiple MyelomaRecruitingNCT04483206Phase 1
- A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.RecruitingNCT04414475Phase 2
- FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)RecruitingNCT04349358Not applicable
- Detection and Pathogenesis of Novel Protein FNot yet recruitingNCT04338386
- Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma DisparitiesRecruitingNCT04314752
- Study of CAR-T Therapy in Older PatientsRecruitingNCT04300998
- BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseRecruitingNCT04271644Phase 1/2
- A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home EnvironmentRecruitingNCT04268199Phase 2
- Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal InsufficiencyRecruitingNCT04240054Phase 2
- Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple MyelomaRecruitingNCT04234022
- Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell MobilizationRecruitingNCT04211259Early Phase 1
- Autologous Stem Cell Transplantation for Patients With AL AmyloidosisEnrolling by invitationNCT04210791
- BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid LymphomaRecruitingNCT04162353Phase 1
- Multiple Myeloma Turkish Prospective Patient RegistryRecruitingNCT04143932
- Activity Levels in Bone Marrow Transplant PatientsRecruitingNCT04115241
- Sleep Apnea in Patients With MGUS and MMRecruitingNCT04114084
- A Study in Leukemia Patients With KaronudibRecruitingNCT04077307Phase 1